Bispecific antibodies as novel bioconjugates

Bioconjugate Chemistry

Volumn 9, Issue 6, 1998, Pages 635-644

  Cao, Y ^a   Suresh, M R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCONJUGATE; BISPECIFIC ANTIBODY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TECHNIQUE; RADIOIMMUNODIAGNOSIS; RADIOIMMUNOTHERAPY;

BIOMOLECULES; MOLECULES;

APPLICATION RANGE; BINDING SPECIFICITIES; BIOCONJUGATES; CROSSLINKER; IMMUNOHISTOCHEMISTRY; RADIOIMMUNOTHERAPY; SECOND GENERATION; SINGLE CHAINS; SINGLE MOLECULE; UNIQUE FEATURES;

ANTIBODIES;

EID: 0032212020     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc980044l     Document Type: Review

References (119)

1. Affleck, K., and Embleton, M. J. (1992) Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines. Br. J. Cancer 65, 838-44.
2. Allard, W. J., Moran, C. A., Nagel, E., Collins, G., and Largen, M. T. (1992) Antigen binding properties of highly purified bispecific antibodies. Mol. Immunol. 29, 1219-27.
3. Anderson, P. M., Crist, W., Hasz, D., Carroll, A. J., Myers, D. E., and Uckun, F. M. (1992) G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 80, 2826-34.
4. Auriol, J., Guesdon, J. L., Mazie, J. C., and Nato, F. (1994) Development of a bispecific monoclonal antibody for use in molecular hybridisation. J. Immunol. Methods 169, 123-33.
5. Azuma, A., Yagita, H., Matsuda, H., Okumura, K., and Niitani, H. (1992) Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity. Cancer Res. 52, 4890-94.
6. Barr, I. G., MacDonald, H. R., Buchegger, F., and von Fliedner, V. (1987) Lysis of tumor cells by the retargeting of murine cytolytic T lymphocytes with bispecific antibodies. Int. J. Cancer 40, 423-9.
7. Berg, J., Lotscher, E., Steimer, K. S., Capon, D. J., Baenziger, J., Jack, H. M., and Wabl, M. (1991) Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc. Natl. Acad. Sci. U.S.A. 88, 4723-7.
8. Berkova, N., Karawajew, L., Korobko, V., Behrsing, O., Micheel, B., Shamborant, O., Stukatcheva, E., and Shingarova, L. (1996) Development of an enzyme immunoassay for the measurement of human tumour necrosis factor-alpha (hTNF-alpha) using bispecific antibodies to hTNF-alpha and horseradish peroxidase. Biotechnol. Appl. Biochem. 23, 163-71.
9. Bolhuis, R. L., Sturm, E., and Braakman, E. (1991) T cell targeting in cancer therapy. Cancer Immunol. Immunother. 34, 1-8.
10. Bolhuis, R. L., Lamers, C. H., Goey, S. H., Eggermont, A. M., Trimbos, J. B., Stoter, G., Lanzavecchia, A., di Re, E., Miotti, S., and Raspagliesi, F., et al. (1992) Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer (Suppl.) 7, 78-81.
11. Bonardi, M. A., Bell, A., French, R. R., Gromo, G., Hamblin, T., Modena, D., Tutt, A. L., and Glennie, M. J. (1992) Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int. J. Cancer (Suppl.) 7, 73-7.
12. Bonardi, M. A., French, R. R., Amlot, P., Gromo, G., Modena, D., and Glennie, M. J. (1993) Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res. 53, 3015-21.
13. Bos, R., and Nieuwenhuizen, W. (1992) Enhanced transfection of a bacterial plasmid into hybridoma cells by electroporation: application for the selection of hybrid hybridoma (quadroma) cell lines. Hybridoma 11, 41-51.
14. Branscomb, E. E., Runge, M. S., Savard, C. E., Adams, K. M., Matsueda, G. R., and Haber, E. (1990) Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator. Thromb. Haemost. 64, 260-6.
15. Brenner, M. B., Trowbridge, I. S., and Strominger, J. L. (1985) Cross-linking of human T cell receptor proteins: association between the T cell idiotype beta subunit and the T3 glycoprotein heavy subunit. Cell 40, 183-90.
16. Canevari, S., Menard, S., Mezzanzanica, D., Miotti, S., Pupa, S. M., Lanzavecchia, A., and Colnaghi, M. I. (1988) Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells. Int. J. Cancer (Suppl.) 2, 18-21.
17. Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Di Re, E. M., Eggermont, A. M., Goey, S. H., Gratama, J. W., and Lamers, C. H., et al. (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 87, 1463-9.
18. Cao, Y., Vinayagamoorthy, T., Noujaim, A. A., and Suresh, M. R. (1995) A rapid nonselective method to generate quadromas by microelectrofusion. J. Immunol. Methods 187, 1-7.
19. Cao, Y., Christian, S., and Suresh, M. R. (1998) Development of bsMAb anti-biotin x anti-HRPO as a universal immunoprobe for detecting biotinylated macromolecules. J. Immunol. Methods (in press).
20. Chamow, S. M., Zhang, D. Z., Tan, X. Y., Mhatre, S. M., Marsters, S. A., Peers, D. H., Byrn, R. A., Ashkenazi, A., and Junghans, R. P. (1994) A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J. Immunol. 153, 4268-80.
21. Chamow, S. M., Zhang, D., Tan, X. Y., Mhatre, S. M., Marsters, S. A., Peers, D. H., Byrn, R. A., Ashkenazi, A., and Junghans, R. P. (1995) A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J. Hematother. 4, 439-46.
22. Chang, D. C. (1989) Cell poration and cell fusion using an oscillating electric field. Biophys. J. 56, 641-52.
23. Charpie, J. R., Runge, M. S., Matsueda, G. R., and Haber, E. (1990) A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase. Biochemistry 29, 6374-8.
24. Chatal, J. F., Faivre-Chauvet, A., Bardies, M., Peltier, P., Gautherot, E., and Barbet, J. (1995) Bifunctional antibodies for radioimmunotherapy. Hybridoma 14, 125-8.
25. Cheong, H. S., Chang, J. S., Park, J. M., and Byun, S. M. (1990) Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem. Biophys. Res. Commun. 173, 795-800.
26. Chetanneau, A., Barbet, J., Peltier, P., Le Doussal, J. M., Gruaz-Guyon, A., Bernard, A. M., Resche, I., Rouvier, E., Bourguet, P., and Delaage, M., et al. (1994) Pretargetted imaging of colorectal cancer recurrences using an 111In-labeled bivalent hapten and a bispecific antibody conjugate. Nucl. Med. Commun. 15, 972-80.
27. Cook, A. G., and Wood, P. J. (1994) Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems. J. Immunol. Methods 171, 227-37.
28. Corvalan, J. R., Smith, W., Gore, V. A., and Brandon, D. R. (1987) Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol. Immunother. 24, 133-7.
29. Cotton, R. G., and Milstein, C. (1973) Letter: Fusion of two immunoglobulin-producing myeloma cells. Nature 244, 42-3.
30. Davico Bonino, L., De Monte, L. B., Spagnoli, G. C., Vola, R., Mariani, M., Barone, D., Moro, A. M., Riva, P., Nicotra, M. R., and Natali, P. G., et al. (1995) Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma [published erratum appears in Int. J. Cancer (1995) 62 (3), 364]. Int. J. Cancer 61, 509-15.
31. De Gast, G. C., Van Houten, A. A., Haagen, I. A., Klein, S., De Weger, R. A., Van Dijk, A., Phillips, J., Clark, M., and Bast, B. J. (1995) Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J. Hematother. 4, 433-7.
32. De Kruif, J., and Logtenberg, T. (1996) Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271, 7630-4.
33. De Lau, W. B., Van Loon, A. E., Heije, K., Valerio, D., and Bast, B. J. (1989) Production of hybrid hybridomas based on HAT(s)-neomycin(r) double mutants. J. Immunol. Methods 117, 1-8.
34. De Lau, W. B., Boom, S. E., Heije, K., Griffioen, A. W., Braakman, E., Bolhuis, R. L., Tax, W. J., Clevers, H., and Bast, B. J. (1992) Heterodimeric complex formation with CD8 and TCR by bispecific antibody sustains paracrine IL-2-dependent growth of CD3+ CD8+ T cells. J. Immunol. 149, 1840-6.
35. Demanet, C., Brissinck, J., De Jonge, J., and Thielemans, K. (1996) Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 87, 4390-8.
36. De Sutter, K., and Fiers, W. (1994) A bifunctional murine:: human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase. Mol. Immunol. 31, 261-7.
37. Deramoudt, E. X., Guard, C., Lepine, N., Alonso, J. M., and Romet-Lemonne, J. L. (1992) Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes. Clin. Exp. Immunol. 89, 310-4.
38. Dillehay, L. E., Mayer, R., Zhang, Y. G., Shao, Y., Song, S. Y., Mackensen, D. G., and Williams, J. R. (1995) Prediction of tumor response to experimental radioimmunotherapy with 90Y in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 33, 417-27.
39. Fanger, M. W., Ball, E. D., and Drakeman, D. L. (1995) Comments on the Fourth International Conference on Bispecific Antibodies and Cellular Cytotoxicity, Duck Key, Florida, March 1-5, 1995 (editorial). J. Hematother. 4, 345-9.
40. Ferrini, S., Prigione, I., Mammoliti, S., Colnaghi, M. I. Menard, S., Moretta, A., and Moretta, L. (1989) Retargeting of T-cell receptor gamma/delta+ lymphocytes against tumor cells by bispecific monoclonal antibodies. Int. J. Cancer (Suppl.) 4, 53-55.
41. French, R. R., Hamblin, T. J., Bell, A. J., Tutt, A. L., and Glennie, M. J. (1995) Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet 346, 223-4.
42. French, R. R., Bell, A. J., Hamblin, T. J., Tutt, A. L., and Glennie, M. J. (1996) Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. Leuk. Res, 20, 607-17.
43. Glennie, M. J., McBride, H. M., Worth, A. T., and Stevenson, G. T. (1987) Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab′ gamma fragments. J. Immunol. 139, 2367-75.
44. Goodwin, D. A. (1987) Pharmacokinetics and antibodies. J. Nucl. Med. 28, 1358-62.
45. Goodwin, D. A., Meares, C. F., Watanabe, N., McTigue, M., Chaovapong, W., Ransone, C. M., Renn, O., Greiner, D. P., Kukis, D. L., and Kronenberger, S. I. (1994) Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraaceti c acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer Res. 54, 5937-46.
46. Gruber, M., Schodin, B. A., Wilson, E. R., and Kranz, D. M. (1994) Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152, 5368-74.
47. Haagen, I. A., van de Griend, R., Clark, M., Geerars, A., Bast, B., and de Gast, B. (1992) Killing of human leukaemia/ lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19) Clin. Exp. Immunol. 90, 368-75.
48. Hayden, M. S., Gilliland, L. K. and Ledbetter, J. A. (1997) Antibody engineering. Curr. Opin. Immunol. 9, 201-212.
49. Hermanson, G. T. (1996) Bioconjugate techniques, Academic Press, NY.
50. Holliger, P., Prospero, T., and Winter, G. (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl. Acad. Sci. U.S.A. 90, 6444-8.
51. Hsieh-Ma, S. T., Eaton, A. M., Shi, T., and Ring, D. B. (1992) In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III. Cancer Res. 52, 6832-9.
52. Imura, Y., Stassen, J. M., Kurokawa, T., Iwasa, S., Lijnen, H. R., and Collen, D. (1992) Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. Blood 79, 2322-9.
53. Jantscheff, P., Winkler, L., Karawajew, L., Kaiser, G., Bottger, V., and Micheel, B. (1993) Hybrid hybridomas producing bispecific antibodies to CEA and peroxidase isolated by a combination of HAT medium selection and fluorescence activated cell sorting. J. Immunol. Methods 163, 91-7.
54. Jung, G., Freimann, U., Von Marschall, Z., Reisfeld, R. A., and Wilmanns, W. (1991) Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur. J. Immunol. 21, 2431-5.
55. Kaneko, T., Fusauchi, Y., Kakui, Y., Masuda, M., Akahoshi, M., Teramura, M., Motoji, T., Okumura, K., Mizoguchi, H., and Oshimi, K. (1993) A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 81, 1333-41.
56. Karawajew, L., Micheel, B., Behrsing, O., and Gaestel, M. (1987) Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter. J. Immunol. Methods 96, 265-70.
57. Karawajew, L., Behrsing, O., Kaiser, G., and Micheel, B. (1988) Production and ELISA application of bispecific monoclonal antibodies against fluorescein isothiocyanate (FITC) and horseradish peroxidase (HRP) J. Immunol. Methods 111, 95-9.
58. Knuth, A., Bernhard, H., Jager, E., Wolfel, T., Karbach, J., Jaggle, C., Strittmatter, W., and Meyer zum Buschenfelde, K. H. (1994) Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3. Eur. J. Cancer 30A, 1103-7.
59. Kohler, G., and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-7.
60. Kontsekova, E., Novak, M., and Kontsek, P. (1992) Bispecific antibodies: present status and possibile applications. Bratis. Lek. Listy 93, 405-10.
61. Koolwijk, P., Rozemuller, E., Stad, R. K., De Lau, W. B., and Bast, B. J. (1988) Enrichment and selection of hybrid hybridomas by Percoll density gradient centrifugation and fluorescent-activated cell sorting. Hybridoma 7, 217-25.
62. Kostelny, S. A., Cole, M. S., and Tso, J. Y. (1992) Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148, 1547-53.
63. Kranenborg, M. H., Boerman, O. C., Oosterwijk-Wakka, J. C., de Weijert, M. C., Corstens, F. H., and Oosterwijk, E. (1995) Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res. 55, 5864-7.
64. Kranz, D. M., Gruber, M., and Wilson, E. R. (1995) Properties of bispecific single chain antibodies expressed in Escherichia coli. J. Hematother. 4, 403-8.
65. Kreutz, F. T., and Suresh, M. R. (1995) Bispecific monoclonal anti-CA125 X anti-peroxidase antibodies in the measurement of the ovarian carcinoma antigen. J. Tumor Marker Oncol. 10, 45-53.
66. Kreutz, F. T., and Suresh, M. R. (1997) Novel bispecific I immunoprobe for rapid and sensitive detection of prostate-specific antigen. Clin. Chem. 43, 649-56.
67. Kreutz, F. T., Wishart, D. S., and Suresh, M. R. (1998a) An efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography. J. Chromatogr., B (in press).
68. Kreutz, F. T., Xu, D. Z., and Suresh, M. R. (1998b) A new method to generate quadromas by electrofusion and FACS sorting. Hybridoma 17, 267-73.
69. Kurokawa, T., Iwasa, S., Kakinuma, A., Stassen, J. M., Lijnen, H. R., and Collen, D. (1991) Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Thromb. Haemost. 66, 684-93.
70. Lanzavecchia, A., and Scheidegger, D. (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol. 17, 105-11.
71. Liu, L., Barth, R. F., Adams, D. M., Soloway, A. H., and Reisfeld, R. A. (1995) Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J. Hematother. 4, 477-83.
72. Liu, M. A., Kranz, D. M., Kurnick, J. T., Boyle, L. A., Levy, R., and Eisen, H. N. (1985) Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 82, 8648-52.
73. Mallender, W. D., Ferreira, S. T., Voss, E. W., Jr., and Coelho-Sampaio, T. (1994) Inter-active-site distance and solution dynamics of a bivalent-bispecific single-chain antibody molecule. Biochemistry 33, 10100-8.
74. McGuinness B. T., Walter G., Fitzgerald K., Schuler P., Mahoney, W., Duncan A. R., Hoogenboom H. R. (1996) Phage diabody repertoires for selection of large numbers of bispecific antibody fragments Natl. Biotechnol. 14, 1149-53.
75. Merchant, A. M., Zhu, Z. P., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., and Carter, P. (1997) An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677-81.
76. Milstein, C., and Cuello, A. C. (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305, 537-40.
77. Nisonoff, A., and Rivers, M. M. (1961) Recombination of a mixture of univalent antibody fragments of different specificity. Arch. Biochem. Biophys. 93, 460-62.
78. Nolan, O., and Kennedy O. R. (1990) Bifunctional antibodies: concept, production and applications. Biochim. Biophys. Acta 1040, 1-11.
79. Ohta, S., Tsukamoto, H., Watanabe, K., Makino, K., Kuge, S., Hanai, N., Habu, S., and Nishimura, T. (1995) Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol. Lett. 44, 35-40.
80. Pak, R. H., Primus, F. J., Rickard-Dickson, K. J., Ng, L. L., Kane, R. R., and Hawthorne, M. F. (1995) Preparation and properties of nido-carborane-specific monoclonal antibodies for potential use in boron neutron capture therapy for cancer. Proc. Natl. Acad. Sci. U.S.A. 92, 6986-90.
81. Piran, U., Silbert-Shostek, D., and Barlow, E. H. (1993) Role of antibody valency in hapten-heterologous immunoassays. Clin. Chem. 39, 879-83.
82. Pluckthun, A. and Pack, P. (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3, 83-105.
83. Rammensee, H. G., Julius, M. H., Nemazee, D., Langhorne, J., Lamers, R., and Kohler, G. (1987) Targeting cytotoxic T cells to antigen-specific B lymphocytes. Eur. J. Immunol. 17, 433-6.
84. Reddy, V. S., and Ford, C. H. (1993) Production of hybrids secreting bispecific antibodies recognising CEA and doxorubicin. Anticancer Res. 13, 2077-83.
85. Rheinnecker M, Hardt C, Iiag L. L., Kufer P, Gruber R., Hoess A, Lupas A., Rottenberger C, Pluckthun A. And Pack P (1996) Multivalent antibody fragments with high functional affinity for a tumor associated carbohydrate antigen. J. Immunol. 157, 2989-2997.
86. Ribeiro-da-Silva, A., Pioro, E. P., and Cuello, A. C. (1991) Substance P- and enkephalin-like immunoreactivities are colocalized in certain neurons of the substantia gelatinosa of the rat spinal cord: an ultrastructural double-labeling study. J. Neurosci. 11, 1068-80.
87. Ridgway, J. B., Presta, L. G., and Carter, P. (1996) Knobs-into-holes engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-21.
88. Roosnek, E., and Lanzavecchia, A. (1989) Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell. J. Exp. Med. 170, 297-302.
89. Roosnek, E., Tunnacliffe, A., and Lanzavecchia, A. (1990) T cell activation by a bispecific anti-CD3/anti-major histocompatibility complex class I antibody. Eur. J. Immunol. 20, 1393-6.
90. Rylatt, D. B., Kemp, B. E., Bundesen, P. G., John, M. A., EJ, O. R., Cottis, L. E., Miles, S. J., Khan, J. M., Dinh, D. P., and Stapleton, D., et al. (1990) A rapid whole-blood immunoassay system. Med. J. Aust. 152, 75-7.
91. Sahin, U., Hartmann, F., Senter, P., Pohl, C., Engert, A., Diehl, V., and Pfreundschuh, M. (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/ anti-alkaline phosphatase monoclonal antibody. Cancer Res. 50, 6944-8.
92. Schmidt, M., Hynes, N. E., Groner, B., and Wels, W. (1996) A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int. J. Cancer 65, 538-46.
93. Schuhmacher, J., Klivenyi, G., Matys, R., Stadler, M., Regiert, T., Hauser, H., Doll, J., Maier-Borst, W., and Zoller, M. (1995) Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res. 55, 115-23.
94. Segal, D. M., Qian, J. H., Garrido, M. A., Perez, P., Winkler, D. F., Wunderlich, J. R., Snider, D. P., Valdayo, M. J., and Titus, J. A. (1988) Targeting of cytotoxic cells against tumors with heterocross-linked, bispecific antibodies. Princess Takamatsu Cancer Res. Fund, Proc. Int. Symp. 19, 323-31.
95. Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beverley, P. C., Feldmann, M., and Carter, P. (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175, 217-25.
96. Smith, W., Jarrett, A. L., Beattie, R. E., and Corvalan, J. R. (1992) Immunoglobulins secreted by a hybrid-hybridoma: analysis of chain assemblies. Hybridoma 11, 87-98.
97. Somasundaram, C., Arch, R., Matzku, S., and Zoller, M. (1996) Development of a bispecific F(ab′)2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity. Cancer Immunol. Immunother. 42, 343-50.
98. Songsivilai, S., and Lachmann, P. J. (1990) Bispecific antibody: a tool for diagnosis and treatment of disease. Clin. Exp. Immunol. 79, 315-21.
99. Songsivilai, S., Clissold, P. M., and Lachmann, P. J. (1989) A novel strategy for producing chimeric bispecific antibodies by gene transfection. Biochem. Biophys. Res. Commun. 164, 271-6.
100. Staerz, U. D., and Bevan, M. J. (1985) Cytotoxic T lymphocyte-mediated lysis via the Fc receptor of target cells. Eur. J. Immunol. 15, 1172-7.
101. Staerz, U. D., and Bevan, M. J. (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. U.S.A. 83, 1453-7.
102. Staerz, U. D., and Bevan, M. J. (1989) Redirecting the cellular immune response. Int. Rev. Immunol. 4, 159-73.
103. Suresh, M. R. (1991) Immunoassays for cancer-associated carbohydrate antigens. Semin. Cancer Biol. 2, 367-77.
104. Suresh, M. R., Cuello, A. C., and Milstein, C. (1986a) Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc. Natl. Acad. Sci. U.S.A. 83, 7989-93.
105. Suresh, M. R., Cuello, A. C., and Milstein, C. (1986b) Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol. 121, 210-28.
106. Tada, H., Toyoda, Y., and Iwasa, S. (1989) Bispecific antibody-producing hybrid hybridoma and its use in one-step immunoassays for human lymphotoxin. Hybridoma 8, 73-83.
107. Takahashi, M., and Fuller, S. A. (1988) Production of murine hybrid-hybridomas secreting bispecific monoclonal antibodies for use in urease-based immunoassays. Clin. Chem. 34, 1693-6.
108. Thirion, S., Motmans, K., Heyligen, H., Janssens, J., Raus, J., and Vandevyver, C. (1996) Mono- and bispecific single-chain antibody fragments for cancer therapy. Eur. J. Cancer Prev. 5, 507-11.
109. Tutt, A., Greenman, J., Stevenson, G. T., and Glennie, M. J. (1991a) Bispecific F(ab′gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells. Eur. J. Immunol. 21, 1351-8.
110. Tutt, A., Stevenson, G. T., and Glennie, M. J. (1991b) Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol. 147, 60-9.
111. Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V., Ernstoff, M. S., Wells, W., Barth, R., Deo, Y., and Fisher, J., et al. (1995) Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J. Hematother. 4, 471-5.
112. Van Dijk, J., Tsuruo, T., Segal, D. M., Bolhuis, R. L., Colognola, R., van de Griend, R. J., Fleuren, G. J., and Warnaar, S. O. (1989) Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells. Int. J. Cancer 44, 738-43.
113. Van Dijk, J., Zegveld, S. T., Fleuren, G. J., and Warnaar, S. O. (1991) Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int. J. Cancer 48, 738-43.
114. Van Osdol, W. V., Sung, C., Dedrick, R. L. and Weinstein, J. N. (1993) A distributed pharmacokinetic model of two-step imaging and treatment protocols: Application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J. Nucl. Med. 34, 1552-64.
115. Weiner, L. M., Clark, J. I., Ring, D. B., and Alpaugh, R. K. (1995) Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J. Hematother. 4, 453-6.
116. Winter, G., and Milstein, C. (1991) Man-made antibodies. Nature 349, 293-9.
117. Wognum, A. W., Lansdorp, P. M., Eaves, A. C., and Krystal, G. (1989) An enzyme-linked immunosorbent assay for erythropoietin using monoclonal antibodies, tetrameric immune complexes, and substrate amplification. Blood 74, 622-8.
118. Wong, J. T., and Colvin, R. B. (1987) Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J. Immunol. 139, 1369-74.
119. Xu, D. Z., Leveugle, B., Kreutz, F. T. and Suresh, M. R. (1997) Mimetic ligand-based affinity purification of immune complexes and immunoconjugates. J. Chromatogr., B 706, 217-29.